Medical Device News Magazine

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

PCR Biosystems, a leading PCR reagent developer, has launched a new range of Bst polymerase reagents that offer greater sensitivity, speed, and specificity in all isothermal amplification applications. IsoFast™ Hot Start Bst Polymerase and associated ready mixes use proprietary AptaLock™ hot start technology to minimise non-specific amplification, leading to highly specific and sensitive results in as little as 30 minutes. A new colourimetric mix also enables analysts to detect results visually, vastly reducing equipment requirements. With these technologies, labs can now get reliable results more quickly, unlocking higher throughput testing.

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase. To avoid these issues, users must design primers carefully, and evaluate many more primer pairs for a single target than they would for standard PCR— both of which can be extremely time-consuming and complex.

To help alleviate these concerns, PCR Biosystems’ newly launched IsoFast™ reagents use AptaLock™, a reversible hot start technology that inhibits polymerase activity below 40 °C. As such, both non-specific amplification and primer dimer formation are minimised. Once the mixture is activated on heating, results can be obtained in as little as half an hour, allowing analysts to achieve highly sensitive, specific, and rapid detection of DNA targets. High-throughput testing is also possible, as reaction plates can be set up at room temperature without any issues.

What’s more, the colour mix contains a pH-based dye that changes colour when the desired target is amplified. As a result, the mix enables labs to visually identify positive or negative results without the need for plate readers or fluorometric PCR instruments. The mix is therefore particularly beneficial for regions where point-of-care or field-testing laboratories lack adequate facilities and instrumentation.

“Existing isothermal mixes present a number of challenges for organisations looking for sensitivity, specificity, and speed in DNA detection,” stated Alex Wilson, Co-founder and Business Development Manager, PCR Biosystems. “With our new mixes, labs get greatly improved specificity and sensitivity in their amplification reactions, so they obtain highly reliable results. Our internal studies show that they can be up to 50% faster than competitor mixes on tested targets too, which can make a critical difference for diagnostic and medical labs that need results quickly.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”